Alkermes Announces Publication of Phase 3 Data for ALKS 5461 for Adjunctive Treatment of Major Depressive Disorder in Molecular Psychiatry

— ALKS 5461 Demonstrated Consistent Profile of Antidepressant Activity, Safety and Tolerability in Two Phase 3 Studies — — New Drug Application for ALKS 5461 Currently Under FDA Review With Target Action Date of Jan. 31, 2019 — DUBLIN, Oct. 29, 2018 /PRNewswire/ -- Alkermes pl...

from PR Newswire: //https://ift.tt/2ESuzFL